Peptide Drug Delivery: Oral, Nasal, and Transdermal Advances

**Disclaimer:** This article is provided for educational and research purposes only. The technologies and compounds discussed are in various stages of development and regulatory review. Nothing in this article constitutes medical advice. All references are to published peer-reviewed research.

Introduction

Peptide therapeutics face a paradox: they are among the most specific and potent drug molecules known, yet their delivery remains one of the greatest challenges in pharmaceutical science. The overwhelming majority of approved peptide drugs require injection --- subcutaneous, intramuscular, or intravenous --- because peptides are rapidly degraded by gastrointestinal proteases, have poor membrane permeability due to their size and hydrophilicity, and undergo extensive hepatic first-pass metabolism. This injection requirement limits patient compliance, restricts self-administration, and contributes to the underutilization of peptide therapies that could benefit far more patients.

The past decade has witnessed a transformation in peptide delivery science. The commercial success of oral semaglutide has proven that oral peptide delivery is achievable. Nasal and transdermal platforms have advanced from laboratory curiosities to clinical-stage programs. The technologies enabling these advances --- permeation enhancers, cell-penetrating peptides, nanoparticle encapsulation, and microneedle arrays --- are now mature enough to support a new generation of non-injectable peptide therapeutics.

The Oral Semaglutide Breakthrough

The approval of oral semaglutide (Rybelsus) in 2019 marked a watershed moment for peptide delivery. For the first time, a peptide drug achieved clinically meaningful oral bioavailability and was approved as a daily oral tablet for a chronic condition (type 2 diabetes). Understanding how this was achieved illuminates both the principles and the remaining challenges of oral peptide delivery.

The key enabling technology was SNAC (sodium N-[8-(2-hydroxybenzoyl)amino]caprylate), an absorption enhancer developed by Emisphere Technologies. SNAC operates through multiple complementary mechanisms: it creates a locally alkaline microenvironment around the tablet in the stomach that protects semaglutide from acid-mediated degradation; it transiently disrupts the gastric epithelial barrier through interaction with cell membrane lipids; and it promotes transcellular absorption of the peptide across gastric epithelial cells. Importantly, the absorption occurs primarily in the stomach, not the small intestine, which represents a departure from most oral drug delivery strategies.

The absolute oral bioavailability of semaglutide with SNAC is approximately 0.4--1%, which would be prohibitively low for most drugs but is viable for semaglutide because of the peptide's extreme potency (active at picomolar concentrations) and long half-life (approximately one week). The PIONEER clinical trial program demonstrated that oral semaglutide at 14 mg daily achieved HbA1c reductions and weight loss comparable to injectable semaglutide 0.5 mg weekly, validating the approach clinically.

However, the SNAC platform has significant limitations. The tablet must be taken on an empty stomach with no more than 120 mL of water, and the patient must fast for at least 30 minutes afterward --- requirements that reduce real-world compliance. The low bioavailability means that the tablet contains 14 mg of semaglutide to achieve plasma levels equivalent to a 0.5 mg injection, representing substantial drug waste. And the absorption-enhancing mechanism is somewhat indiscriminate: any food, beverages, or other medications present in the stomach during the absorption window can interfere with uptake.

Next-Generation Oral Delivery Technologies

Multiple approaches are being developed to overcome the limitations of first-generation oral peptide delivery. These can be broadly categorized as chemical modification strategies, formulation-based approaches, and device-based solutions.

Chemical modifications include backbone alterations that confer protease resistance while maintaining receptor binding. N-methylation of specific amide bonds, incorporation of D-amino acids at protease-sensitive positions, and cyclization (as seen with cyclosporine A, which achieves approximately 30% oral bioavailability naturally due to its cyclic structure and N-methylated backbone) can dramatically improve metabolic stability. Prodrug strategies, where the peptide is reversibly masked with lipophilic moieties that are cleaved after absorption, can enhance membrane permeability.

Cell-penetrating peptides (CPPs) represent an elegant biological approach. These short peptides (typically 5--30 amino acids, rich in arginine and lysine) can traverse cell membranes and carry attached cargo intracellularly. Penetratin (from the Drosophila Antennapedia homeodomain), TAT (from HIV-1 transactivator protein), and synthetic polyarginines have all been conjugated to therapeutic peptides to enhance oral absorption. The challenges include ensuring the CPP-cargo conjugate survives GI transit and demonstrating that CPP-mediated uptake produces therapeutically relevant systemic peptide levels.

Nanoparticle encapsulation offers protection from degradation and can enable targeted release. PLGA (poly-lactic-co-glycolic acid) nanoparticles, chitosan-based nanoparticles, and solid lipid nanoparticles have all shown improved oral bioavailability of encapsulated peptides in preclinical studies. A 2020 study by Banerjee et al. demonstrated that insulin-loaded PLGA nanoparticles coated with chitosan achieved a relative oral bioavailability of 11.2% in diabetic rats, compared to less than 1% for unformulated oral insulin. The mucoadhesive properties of chitosan prolong intestinal residence time, while the nanoparticle matrix protects the peptide from enzymatic degradation.

Perhaps the most innovative approach is the ingestible device. Lyndra Therapeutics has developed a pill-sized device that unfolds into a star shape in the stomach, providing sustained release of peptide drugs over days to weeks before eventually dissolving. The MIT-based SOMA (self-orienting millimeter-scale applicator) device, developed by Robert Langer's group, orients itself against the gastric wall and delivers a peptide-loaded needle directly into the gastric mucosa, achieving bioavailability comparable to subcutaneous injection in animal models. A related technology, LUMI (luminal unfolding microneedle injector), delivers peptides through arrays of millimeter-scale needles that penetrate the intestinal epithelium after the capsule dissolves in the small intestine.

Nasal Peptide Delivery

The nasal route offers several inherent advantages for peptide delivery: the nasal mucosa has a large surface area (approximately 150 cm squared), rich vascular supply, and avoids hepatic first-pass metabolism. The thin, permeable nasal epithelium --- particularly in the posterior, non-ciliated olfactory region --- permits absorption of molecules that would not cross the GI epithelium. Additionally, the nose-to-brain pathway via the olfactory and trigeminal nerves offers direct CNS access for neuropeptides, bypassing the blood-brain barrier.

Several peptide drugs already exploit nasal delivery clinically. Desmopressin (DDAVP) nasal spray achieves approximately 3--5% bioavailability via the nasal route and has been used for decades in diabetes insipidus and nocturnal enuresis. Nafarelin nasal spray (for endometriosis, approximately 2.8% bioavailability) and calcitonin nasal spray (for osteoporosis, approximately 3% bioavailability) demonstrate the viability of nasal peptide delivery for chronic conditions.

In the peptide research community, the nasal route has attracted particular attention for neuropeptides. Semax (Met-Glu-His-Phe-Pro-Gly-Pro), a synthetic analog of ACTH(4-10), and selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro), a tuftsin analog, were both developed at the Institute of Molecular Genetics in Moscow and are administered intranasally. Preclinical research has demonstrated that intranasally administered semax increases brain-derived neurotrophic factor (BDNF) levels in the hippocampus and cerebral cortex and modulates dopaminergic, serotonergic, and cholinergic neurotransmission. The nasal route is particularly appropriate for these peptides because their target is the central nervous system, and nose-to-brain transport provides more direct access than systemic administration.

Absorption enhancers can dramatically improve nasal peptide bioavailability. Alkylsaccharides (dodecyl maltoside, tetradecyl maltoside) have been shown to transiently and reversibly increase nasal epithelial permeability, achieving bioavailability improvements of 5-to-20-fold for various peptides. Intravail (alkylsaccharide-based enhancer) has been incorporated into several clinical-stage nasal peptide formulations. Tight junction modulators, including the zonula occludens toxin-derived peptide AT-1002 (larazotide), can transiently open paracellular pathways for peptide absorption without causing lasting epithelial damage.

Transdermal and Microneedle Delivery

The skin represents an enormous potential delivery surface (approximately 1.7 square meters in adults) but presents a formidable barrier in the stratum corneum --- the 10-to-20-micrometer-thick outermost skin layer composed of dead, flattened keratinocytes embedded in a lipid matrix. This barrier effectively excludes molecules larger than approximately 500 Da, ruling out passive transdermal delivery of most peptides.

Microneedle technology has overcome this barrier by creating painless microchannels through the stratum corneum that allow peptide access to the underlying viable epidermis and dermis. Microneedles are typically 100--900 micrometers in length --- long enough to penetrate the stratum corneum but short enough to avoid the nerve endings and blood vessels of the deeper dermis, making application painless.

Several microneedle architectures are in development for peptide delivery. Dissolving microneedles, fabricated from biocompatible polymers (hyaluronic acid, carboxymethyl cellulose, polyvinylpyrrolidone) with peptide drug incorporated into the needle matrix, dissolve after insertion and release their payload over minutes to hours. Coated microneedles have peptide drug deposited on the surface of solid metal or polymer needles, providing bolus release upon insertion. Hollow microneedles function as miniaturized hypodermic needles, allowing controlled infusion of liquid peptide formulations through the skin.

Zosano Pharma developed a titanium microneedle patch (Qtrypta) for zolmitriptan delivery in migraine, demonstrating the feasibility of peptide delivery through coated microneedle arrays. While zolmitriptan is a small molecule rather than a peptide, the platform has been adapted for parathyroid hormone (PTH 1-34, teriparatide) delivery, achieving bioavailability of approximately 40% in clinical studies --- substantially higher than oral delivery and comparable to subcutaneous injection. Phase III trials of a PTH microneedle patch for osteoporosis showed non-inferiority to daily teriparatide injections in bone mineral density outcomes.

Iontophoresis --- the application of a mild electric current to drive charged peptide molecules through the skin --- offers another transdermal approach. The technique exploits the net charge that peptides carry at physiological pH. Electroporation, which uses brief high-voltage pulses to transiently create pores in the stratum corneum, can increase transdermal peptide flux by several orders of magnitude. Combination approaches (microneedles plus iontophoresis, or nanoparticles plus microneedles) are showing synergistic enhancement of peptide delivery in preclinical studies.

PEGylation and Half-Life Extension

While not a delivery route per se, PEGylation (conjugation of polyethylene glycol chains) fundamentally alters peptide pharmacokinetics and remains a critical enabling technology. PEGylation increases the hydrodynamic radius of a peptide, reducing renal clearance; shields it from proteolytic degradation; and can reduce immunogenicity by masking epitopes. The success of PEGylated proteins (PEG-interferon, PEG-filgrastim) established the approach, which is now being applied to smaller peptides.

Site-specific PEGylation --- attaching PEG at defined positions to minimize impact on receptor binding --- has improved with advances in bioconjugation chemistry. Non-natural amino acid incorporation (using amber codon suppression) allows PEG attachment at positions that do not affect bioactivity. Releasable PEG linkers that are cleaved in vivo, releasing the unmodified active peptide, combine the pharmacokinetic benefits of PEGylation with the full potency of the native peptide.

Alternatives to PEGylation are also emerging. XTEN (an unstructured recombinant polypeptide of approximately 864 amino acids) and PASylation (fusion of proline-alanine-serine repeats) can extend half-lives comparably to PEGylation without the theoretical concerns about anti-PEG antibody formation that have been observed with some PEGylated therapeutics.

The Convergence Ahead

The future of peptide delivery lies in convergence: combining multiple technologies to achieve oral or non-invasive administration with high bioavailability. Nanoparticle-encapsulated peptides delivered via microneedle patches, CPP-conjugated peptides formulated with nasal absorption enhancers, and orally administered peptide-loaded devices that inject directly into the GI mucosa all represent combinations currently in development.

The commercial pressure driving these innovations is immense. The global peptide therapeutics market exceeds $70 billion annually, and the GLP-1 agonist experience demonstrates that removing the injection barrier can dramatically expand patient populations. As delivery technologies mature, peptides that are currently limited to hospital or specialist-clinic administration could become accessible as self-administered oral, nasal, or patch formulations --- a transformation that would reshape both the pharmaceutical industry and patient access to peptide-based therapies.

Summary

Peptide drug delivery is undergoing a paradigm shift from injection-dependent administration to non-invasive routes. Oral delivery, proven commercially by semaglutide/SNAC and advancing through nanoparticles, cell-penetrating peptides, and ingestible devices, is the most commercially significant frontier. Nasal delivery offers advantages for neuropeptides and rapid-onset applications. Transdermal microneedle patches have achieved bioavailability comparable to injection for certain peptides. Half-life extension through PEGylation and alternative strategies underpins all delivery routes by reducing the frequency of administration. The convergence of these technologies promises a future where the injection barrier no longer limits the therapeutic potential of the peptide class.

*This article is provided for informational and research purposes only. Viking Labs does not sell products intended for human consumption, and nothing in this article should be construed as medical advice.*